$90 Million to U. of C. Meant to 'Alter the Course of Cancer'
The Chicago Tribune reports that cancer researchers at the University of Chicago will get a substantial boost Monday, when an international nonprofit plans to announce that the university and five other leading institutions will each receive $90 million to advance new treatments aimed at eradicating cancer.
The $540 million gift from Ludwig Cancer Research, a fund created by the late billionaire Daniel Ludwig, comes at a time when government and private funding for medical research is on the decline.
"We're here to alter the course of cancer," said Ed McDermott, a Ludwig trustee and president and CEO of the Ludwig Institute for Cancer Research, a sister organisation that has more than 600 cancer researchers at dedicated labs around the world. "This funding will be available for those scientists for the indefinite future without having to worry about whether their research is going to be funded next year."
The gift adds to a $120 million endowment in 2006 that created Ludwig Centers at the U. of C., Johns Hopkins University, Harvard University, Massachusetts Institute of Technology, Memorial Sloan-Kettering Cancer Center and Stanford University.
The Chicago research center, headed by radiation oncologist Dr Ralph Weichselbaum and Geoffrey Greene, a molecular biologist, has now received a total of $110 million from Ludwig, which it says should fund in perpetuity continuing study of the disease.
The Ludwig endowment comes at a crucial time for research institutions like the U. of C., which are finding it increasingly difficult to secure grants and other funding to support biomedical research.
"At this time in the history of federal research dollars, the Ludwig funding has created a remarkable opportunity for me and others here to pursue topics, technologies and other initiatives that we just can't get through federal funding," Greene said in an interview. "It's really such a tremendous advantage."
Greene and Weichselbaum said the new funding will help the Chicago research center accelerate and advance its continuing body of research on metastasis, the process by which cancer cells migrate from a primary tumor to distant sites in the body.
The U. of C. plans to use the money to hire researchers, technicians and scientists and purchase equipment. The grant also provides a unique flexibility to pursue unconventional research that other entities often do not fund.
"It's pivotal funding at a time when I think it would have been very hard (to continue this research) otherwise," Weichselbaum said. "The entirety of science revolves around fresh ideas and new infusions of talent, and I think universities are finding this increasingly difficult."
The Ludwig Center is inside the U. of C.'s Gwen and Jules Knapp Center for Biomedical Discovery, which opened in 2009.
The latest funding should enable each center to build a self-sustaining endowment that will yield about $4 million to $5 million in annual research funds in the near term, with amounts growing in later years as their endowments grow, the fund said.
Each university will be responsible for managing its own endowment investments.
Although each center has its own specific focus in the disease category, they commonly collaborate to share theories and discoveries about the nature of cancer and better ways to treat it.
"The whole purpose of this funding is meant to be transformative," McDermott said. "It is meant to relieve investigators from being wholly reliant on short-term grant funding to enable more innovative, higher-risk research."
In a typical grant process, researchers have shorter time frames — typically about three years — to conduct studies and show results in order to get re-funded, McDermott said. The practice "tends to encourage incrementalism."
Instead, he said, the Ludwig money aims for major breakthroughs.
The latest appointments and promotions across the pharmaceutical supply chain.
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors stateDoctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts.
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers?
Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government.
In an open letter to the European Commission, Medicines for Europe calls for a new medicine security contract with their goal to improve access to medicine and ensure a secure supply chain to Europe.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance